A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer

Table 1 Demographic and clinical baseline characteristics of all randomized patients with non-squamous NSCLC (maintenance phase ^a )

Abbreviations: BSC = best supportive care; ECOG PS = Eastern Cooperative Oncology Group Performance Status.
Note: The sum of percentages for some characteristics do not add up to 100% due to rounding.
^aMaintenance phase was defined as visit 5 to the visit prior to the post-treatment phase (i.e. the data of progression or the start of a new anti-cancer therapy treatment).
^bBased on TNM Classification, 6^th edition.
^cThe best overall tumor response during the induction therapy phase. This was used as the stratification factor for randomization to one of the maintenance phase arms.

ISSN: 1471-2407